Research and development spending versus revenues after approval for CFTR modulators
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.10.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Jonathan Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom. Electronic address: jyg17@ic.ac.uk. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Drug Development, Biomedical Research. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, NIHR Imperial Biomedical Research Centre.
Abstract (Originalsprache)
BACKGROUND: The high prices of CFTR modulators present barriers to access for people with cystic fibrosis (CF), especially those in low- and middle-income countries. Costs of research and development (R&D) are often cited as key drivers of drug pricing. In the case of CFTR modulators, circumstances allow for a meaningful comparison of pre-marketing R&D spending and post-approval product revenues. METHODS: Data on R&D expenditure and CFTR modulator revenues from Q3 2001 (the initial acquisition of CFTR modulator research) until 2024 were extracted from the originator company's Securities and Exchange Commission filings. All values were inflation-adjusted to 2024. Cost of capital was incorporated at a discount rate of 10.5 %, with rates of 7 % and 14 % modelled for sensitivity analysis. RESULTS: Total out-of-pocket R&D expenditure prior to the successful marketing of elexacaftor/tezacaftor/ivacaftor in Q3 2019 was $18.5 billion. Cost of capital was estimated at $24.8 [13.2-41.6] billion. Actual costs associated with CFTR modulators are likely substantially lower than total R&D spending. Cumulative CFTR modulator revenues from 2012-24 were $63.8 billion, surpassing R&D expenditure in Q2 2020. At over $10.2 billion annually, elexacaftor/tezacaftor/ivacaftor represents one of the highest revenue pharmaceutical products currently on the market. CONCLUSION: High revenues mean that R&D costs associated with CFTR modulators have been recouped early in their commercial lifespan. However, their pricing threatens global health equity for people with CF and the financial sustainability of health systems. In the eve of genetic therapies for CF and other rare diseases, sustainable solutions balancing equitable access and financial reward are urgently required. FUNDING: JG is supported by the HEE Specialised Foundation Programme and acknowledges infrastructure support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom. Electronic address: jyg17@ic.ac.uk.
- School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom.
- Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom.
Förderung
- National Institute for Health and Care Research
- NIHR Imperial Biomedical Research Centre
Zitieren
APA
Guo, J., Hennessy, G., Young, B., & Hill, A. (2025). Research and development spending versus revenues after approval for CFTR modulators. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.10.008
Vancouver
Guo J, Hennessy G, Young B, Hill A. Research and development spending versus revenues after approval for CFTR modulators. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.10.008
BibTeX
@article{Guo2025,
author = {Guo, Jonathan and Hennessy, Grace and Young, Benedict and Hill, Andrew},
title = {Research and development spending versus revenues after approval for CFTR modulators},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.10.008}
}
EUVIMED